ReviewGaceta sanitaria2022
[Biomedical research and innovation and COVID-19 syndemic. SESPAS Report 2022].
Review in Gaceta sanitaria, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Public Health and Health Administration in the COVID-19 pandemic. SESPAS Report 2022].Gaceta sanitaria · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the response in research and innovation (R&I) against the COVID-19 syndemic at the national level, contextualized internationally.
methodGuided narrative review.
resultsIn the COVID-19 syndemic, pressure has been put on the scientific community in general, and the innovative biomedical community in particular, to provide solutions, especially biotechnological products. Most of the recommendations of expert panels are not oriented to a biotechnological response (which must also exist), but to governance, organizational, socio-economic measures, and support for public health infrastructures. There is a significant deficit in the inclusion of sex/gender perspective in COVID-19 R&I. The COVID-19 syndemic has offered a (wasted) opportunity to promote research and innovation from an epidemiological perspective against infectious outbreaks with the potential to provoke a crisis in public health, claiming leadership from epidemiology. It is necessary to assess whether the large investment in biomedical R&I aimed at personalized medicine can be efficiently integrated into public health providers in the face of health crises.
conclusionsIt is urgent to design a R&I strategy in Spain aligned with internationally available funds, but providing the country with maximum independence in order to face critical situations for public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.